300+ Genes
1 Blood Draw
Now FDA-Approved

DEMONSTRATED CLINICAL OUTCOMES DATA

FoundationOne Liquid CDx helps guide treatment strategies for advanced cancer patients by analyzing 300+ genes from just two tubes of blood — making it the most comprehensive FDA-approved liquid biopsy on the market.

Companion diagnostic claims across multiple targeted therapies and cancer indications

Comprehensive Panel

Analyzes 324 genes* from two tubes of blood to provide fast, convenient access to comprehensive results that can inform treatment strategies.

Includes results from genomic signatures:
- Blood Tumor Mutational Burden (bTMB)
- Microsatellite Instability High (MSI-H)
- Tumor Fraction

Improved Outcomes

In the TRITON2 Clinical Trial

46% Objective Response Rate for advanced prostate cancer patients who tested positive for BRCA1/2 alterations and treated with RUBRACA (rucaparib)†

Proven Quality

To receive our FDA approval and demonstrate evidence of our high-quality testing, we ran over 7,500 validation samples covering over 30,000 unique genomic variants across more than 30 cancer indications.

Proven Portfolio

Only Foundation Medicine offers an

FDA-approved portfolio of tissue- and blood-based comprehensive genomic profiling tests for all solid tumors — with Medicare coverage for qualifying patients.†

† FoundationOne Liquid CDx is FDA-approved to report substitutions and indels in 311 genes, including rearrangements and copy number losses only in BRCA1/2. Comprehensive results across all 324 genes, including bTMB, MSI-H status, and tumor fraction are reported in the professional services section of the report.

† Medicare and Medicare Advantage members have coverage in accordance with the Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) criteria.

FOR MORE DETAILED INFORMATION VISIT foundationmedicine.com/F1LCDx
Includes Clinically Relevant Genes and Biomarkers
For full list of 324 genes, visit foundationmedicine.com/FILCDx

<table>
<thead>
<tr>
<th>NSCLC</th>
<th>PROSTATE</th>
<th>BREAST</th>
<th>COLORECTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALK</td>
<td>ATM</td>
<td>BRCA1</td>
<td>BRAF</td>
</tr>
<tr>
<td>BRAF</td>
<td>BARD1</td>
<td>NTRK2</td>
<td>ERBB2</td>
</tr>
<tr>
<td>EGFR</td>
<td>RET</td>
<td>NTRK3</td>
<td>Kras</td>
</tr>
<tr>
<td>ERBB2</td>
<td>BRCA2</td>
<td>PIK3CA</td>
<td>NTRK1</td>
</tr>
<tr>
<td>KRAS</td>
<td>BRCA2</td>
<td>RAD51C</td>
<td>NRAS</td>
</tr>
<tr>
<td>MET</td>
<td>CDK12</td>
<td>PALB2</td>
<td>NTRK3</td>
</tr>
<tr>
<td>NTRK1</td>
<td>CHEK1</td>
<td>RAD51D</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CHEK2</td>
<td>RAD51L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FANCL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FoundationOne Liquid CDx is an FDA-approved companion diagnostic for 3 therapies in NSCLC and 1 in prostate cancer.

*Only select intronic or non-coding regions of BRCA1/2.

Sample Report

FoundationOne Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment.

Rubraca® is a registered trademark of Clovis Oncology.

References

© 2020 Foundation Medicine, Inc. | Foundation Medicine and FoundationOne are registered trademarks of Foundation Medicine, Inc. www.foundationmedicine.com | Tel. 888.988.3639 | Fax 617.418.2290 | US-FLDX-2000039